X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   TEVA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
TEVA PHARMA
Dec-13
VENUS REMEDIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1263,001-   
Low Rs612,607-   
Sales per share (Unadj.) Rs301.81,722.1-  
Earnings per share (Unadj.) Rs-24.9107.6-  
Cash flow per share (Unadj.) Rs2.5246.8-  
Dividends per share (Unadj.) Rs094.18-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs293.31,913.0-  
Shares outstanding (eoy) m12.34848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.6 19.0%   
Avg P/E ratio x-3.826.1 -14.4%  
P/CF ratio (eoy) x36.711.4 323.4%  
Price / Book Value ratio x0.31.5 21.8%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m1,1542,377,546 0.0%   
No. of employees `0000.944.9 2.1%   
Total wages/salary Rs m3930-   
Avg. sales/employee Rs Th4,026.132,492.5 12.4%   
Avg. wages/employee Rs Th425.00-   
Avg. net profit/employee Rs Th-331.82,029.8 -16.3%   
INCOME DATA
Net Sales Rs m3,7241,460,373 0.3%  
Other income Rs m230-   
Total revenues Rs m3,7471,460,373 0.3%   
Gross profit Rs m395399,924 0.1%  
Depreciation Rs m338118,043 0.3%   
Interest Rs m35428,684 1.2%   
Profit before tax Rs m-275253,197 -0.1%   
Minority Interest Rs m01,150 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-166,210 0.0%   
Tax Rs m32-3,091 -1.0%   
Profit after tax Rs m-30791,228 -0.3%  
Gross profit margin %10.627.4 38.7%  
Effective tax rate %-11.5-1.2 940.2%   
Net profit margin %-8.26.2 -131.9%  
BALANCE SHEET DATA
Current assets Rs m2,638986,331 0.3%   
Current liabilities Rs m2,305860,164 0.3%   
Net working cap to sales %8.98.6 103.5%  
Current ratio x1.11.1 99.8%  
Inventory Days Days13591 149.2%  
Debtors Days Days4696 48.3%  
Net fixed assets Rs m4,871476,990 1.0%   
Share capital Rs m1233,595 3.4%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,6191,622,198 0.2%   
Long term debt Rs m1,374746,721 0.2%   
Total assets Rs m7,5093,337,421 0.2%  
Interest coverage x0.29.8 2.3%   
Debt to equity ratio x0.40.5 82.5%  
Sales to assets ratio x0.50.4 113.3%   
Return on assets %0.63.6 17.6%  
Return on equity %-8.55.6 -150.8%  
Return on capital %1.64.9 32.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m514232,708 0.2%  
From Investments Rs m-123-82,458 0.1%  
From Financial Activity Rs m-387-279,149 0.1%  
Net Cashflow Rs m4-128,899 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare VENUS REMEDIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare VENUS REMEDIES With: WOCKHARDT LTD.  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  ALKEM LABORATORIES  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 19, 2018 02:21 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS